{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:23Z","timestamp":1781835143300,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T00:00:00Z","timestamp":1473638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T00:00:00Z","timestamp":1473638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Glaukos Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To examine outcomes through 36\u00a0months in phakic eyes with newly diagnosed primary open-angle glaucoma (POAG) na\u00efve to therapy randomized to treatment with two trabecular micro-bypass stents or topical prostaglandin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Subjects with POAG na\u00efve to therapy, with intraocular pressure (IOP) \u226521 and \u226440\u00a0mmHg, were randomized to implantation of two stents or travoprost. Additional medication was to be prescribed post-treatment for elevated IOP or glaucomatous optic nerve findings. Of 101 randomized subjects, 100 subjects were followed for 24\u00a0months and 73 subjects were followed for 36\u00a0months. Follow-up on all subjects is ongoing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this randomized cohort of 101 POAG subjects, 54 subjects underwent 2-stent surgery and 47 received topical travoprost. Mean pre-treatment IOP was 25.5\u00a0\u00b1\u00a02.5\u00a0mmHg in stent-treated eyes and 25.1\u00a0\u00b1\u00a04.6\u00a0mmHg in medication-treated eyes. By 3\u00a0years, mean IOP was 14.6\u00a0mmHg in stent eyes (with medication added in 6 eyes) and 15.3\u00a0mmHg in travoprost eyes (with a second medication added in 11 eyes). In the subset of eyes that did not require additional medical therapy, mean IOP was 14.5\u00a0mmHg and 15.7\u00a0mmHg in the respective groups. Ninety-one percent of stent eyes had 3-year IOP \u226418\u00a0mmHg without additional therapy (62%\u00a0\u2264\u00a015\u00a0mmHg) and 79% of travoprost eyes had 3-year IOP \u226418\u00a0mmHg (21%\u00a0\u2264\u00a015\u00a0mmHg). Safety was favorable in both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this prospective, randomized comparison of subjects with newly diagnosed POAG na\u00efve to therapy, substantial IOP reduction with a favorable low complication rate was shown through 3\u00a0years after either 2 trabecular stents implanted as the sole procedure or topical travoprost therapy. These data suggest 2-stent implantation may be a viable initial treatment option comparable to topical prostaglandin in newly diagnosed POAG patients.<\/jats:p>\n                <jats:p>Trial registration: ClinicalTrials.gov identifier, NCT01443988.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Funding<\/jats:title>\n                <jats:p>Glaukos Corporation, Laguna Hills, CA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40123-016-0065-3","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T11:46:35Z","timestamp":1473680795000},"page":"161-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months"],"prefix":"10.1007","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct01443988","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Steven D.","family":"Vold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilit","family":"Voskanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Tetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Auffarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal Ike K.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hady","family":"Saheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,12]]},"reference":[{"issue":"11 Suppl","key":"65_CR1","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","volume":"116","author":"JC Tsai","year":"2009","unstructured":"Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30\u20136.","journal-title":"Ophthalmology"},{"key":"65_CR2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308\u201316.","journal-title":"Ophthalmology"},{"key":"65_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajo.2003.10.035","volume":"137","author":"G Reardon","year":"2004","unstructured":"Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a\u00a0managed care population. Am J Ophthalmol. 2004;137:3\u201312.","journal-title":"Am J Ophthalmol"},{"key":"65_CR4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","volume":"140","author":"BL Nordstrom","year":"2005","unstructured":"Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598\u2013606.","journal-title":"Am J Ophthalmol"},{"key":"65_CR5","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1167\/iovs.07-0290","volume":"48","author":"DS Friedman","year":"2007","unstructured":"Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"65_CR6","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.ajo.2003.10.034","volume":"137","author":"GF Schwartz","year":"2004","unstructured":"Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open angle glaucoma suspects. Am J Ophthalmol. 2004;137:S13\u20136.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"65_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2009.08.011","volume":"149","author":"SL Mansberger","year":"2010","unstructured":"Mansberger SL. Are you compliant with addressing glaucoma adherence? Am J Ophthalmol. 2010;149(1):1.","journal-title":"Am J Ophthalmol"},{"key":"65_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/bjo.2004.052795","volume":"89","author":"M Nagar","year":"2005","unstructured":"Nagar M, Ogunyomade A, O\u2019Brart DP, et al. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005;89:1413\u20137.","journal-title":"Br J Ophthalmol"},{"key":"65_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/ICU.0b013e32834ff1e7","volume":"23","author":"H Saheb","year":"2012","unstructured":"Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23:96\u2013104.","journal-title":"Curr Opin Ophthalmol"},{"key":"65_CR10","unstructured":"Regulatory Affairs Division, Glaukos Corporation, Laguna Hills, CA, USA. Data on file."},{"key":"65_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcrs.2009.10.031","volume":"36","author":"AM Fea","year":"2010","unstructured":"Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma. J Cataract Refract Surg. 2010;36:407\u201312.","journal-title":"J Cataract Refract Surg"},{"key":"65_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ophtha.2010.07.007","volume":"118","author":"TW Samuelson","year":"2011","unstructured":"Samuelson TW, Katz LJ, Wells JM, Duh Y-J, Giamporcaro JE. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118:459\u201367.","journal-title":"Ophthalmology"},{"key":"65_CR13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jcrs.2012.03.025","volume":"38","author":"ER Craven","year":"2012","unstructured":"Craven ER, Katz LJ, Wells JM, Giamporcaro JE. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg. 2012;38:1339\u201345.","journal-title":"J Cataract Refract Surg"},{"key":"65_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/bjophthalmol-2011-300218","volume":"96","author":"P Arriola-Villalobos","year":"2012","unstructured":"Arriola-Villalobos P, Martinez-de-la-Casa J, Diaz-Valle D, et al. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. Br J Ophthalmol. 2012;96:645\u20139.","journal-title":"Br J Ophthalmol"},{"key":"65_CR15","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1016\/j.jcrs.2015.06.032","volume":"41","author":"TH Neuhann","year":"2015","unstructured":"Neuhann TH. Trabecular micro-bypass stent implantation during small-incision cataract surgery for open-angle glaucoma ocular hypertension: long-term results. J Cataract Refract Surg. 2015;41:2664\u201371.","journal-title":"J Cataract Refract Surg"},{"key":"65_CR16","doi-asserted-by":"crossref","unstructured":"Fea AM, Consolandi G, Zola M, et al. Micro-bypass implantation for primary open-angle glaucoma combined with phacoemulsification: 4-year follow-up. J Ophthalmol. 2015. Article ID 795357. http:\/\/dx.doi.org\/10.1155\/2015\/795357. Accessed July 12, 2016.","DOI":"10.1155\/2015\/795357"},{"key":"65_CR17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/112067210901900311","volume":"19","author":"D Spiegel","year":"2009","unstructured":"Spiegel D, Wetzel W, Neuhann T, et al. Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery. Eur J Ophthalmol. 2009;19:393\u20139.","journal-title":"Eur J Ophthalmol"},{"issue":"11","key":"65_CR18","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.jcrs.2012.07.017","volume":"38","author":"GW Belovay","year":"2012","unstructured":"Belovay GW, Naqi A, Chan BJ, Rateb M, Ahmed II. Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucoma. J Cataract Refract Surg. 2012;38(11):1911\u20137.","journal-title":"J Cataract Refract Surg"},{"key":"65_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jcrs.2014.07.004","volume":"40","author":"II Ahmed","year":"2014","unstructured":"Ahmed II, Katz LJ, Chang DF, et al. Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle glaucoma. J Cataract Refract Surg. 2014;40:1295\u2013300.","journal-title":"J Cataract Refract Surg"},{"key":"65_CR20","first-page":"2057","volume":"9","author":"ED Donnenfeld","year":"2015","unstructured":"Donnenfeld ED, Solomon KD, Voskanyan L, et al. A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma. Clin Ophthalmol. 2015;9:2057\u201365.","journal-title":"Clin Ophthalmol."},{"key":"65_CR21","first-page":"2313","volume":"9","author":"LJ Katz","year":"2015","unstructured":"Katz LJ, Erb C, Carceller Guillamet AC, et al. Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication. Clin Ophthalmol. 2015;9:2313\u201320.","journal-title":"Clin Ophthalmol"},{"key":"65_CR22","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jamaophthalmol.2013.5059","volume":"131","author":"E Rulli","year":"2013","unstructured":"Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures. A systematic review and meta-analysis. JAMA Ophthalmol. 2013;131:1573\u201382.","journal-title":"JAMA Ophthalmol."},{"issue":"4","key":"65_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/s-0034-1368214","volume":"231","author":"H H\u00f6h","year":"2014","unstructured":"H\u00f6h H, Grisanti S, Grisanti S, Rau M, Ianchulev S. Two-year clinical experience with the CyPass micro-stent: safety and surgical outcomes of a novel supraciliary\u00a0micro-stent. Klin Monbl Augenheilkd. 2014;231(4):377\u201381.","journal-title":"Klin Monbl Augenheilkd."},{"key":"65_CR24","unstructured":"Sarkisian S. Combined cataract surgery and supraciliary microstent implantation for open-angle glaucoma: multicenter 3-year results. Presented at 2016 American Society of Cataract and Refractive Surgeons, May, 2016, New Orleans, LA, USA."},{"key":"65_CR25","unstructured":"Vold S. Prospective, randomized evaluation of microinvasive glaucoma surgery (MIGS) with two trabecular microbypass stents vs. prostaglandin in open-angle or pseudoexfoliative glaucoma or ocular hypertension na\u00efve to therapy. Poster presented at 2015 Annual Meeting of the American Glaucoma Society, February 26\u2014March 1, 2015, Coronado, CA."},{"key":"65_CR26","unstructured":"http:\/\/www.clintrials.gov. Accessed July 20, 2016."},{"key":"65_CR27","unstructured":"Terminology and guidelines for glaucoma. ISBN 978-88-98320-05-09. Copyright 2014 European Glaucoma Society. http:\/\/www.eugs.org. Accessed July 22, 2016."},{"key":"65_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ophtha.2008.09.004","volume":"116","author":"CO Okeke","year":"2009","unstructured":"Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically. The Travatan dosing aid study. Ophthalmology. 2009;116:191\u20139.","journal-title":"Ophthalmology"},{"key":"65_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533\u201340.","journal-title":"Am J Ophthalmol"},{"key":"65_CR30","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","volume":"116","author":"JC Tsai","year":"2009","unstructured":"Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116:S30\u20136.","journal-title":"Ophthalmology"},{"key":"65_CR31","unstructured":"Red Book \u2122. Ann Arbor: Truven Health Analytics; 2013. http:\/\/micromedex.com\/products\/product-suites\/clinical-knowledge\/redbook. Accessed July 6, 2016."},{"key":"65_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.survophthal.2009.03.006","volume":"55","author":"S Salim","year":"2010","unstructured":"Salim S, Shields MB. Glaucoma and systemic diseases. Surv Ophthalmol. 2010;55:64\u201377.","journal-title":"Surv Ophthalmol"},{"key":"65_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ajo.2015.04.041","volume":"160","author":"J Peace","year":"2015","unstructured":"Peace J, Ahlberg P, Wagner M, et al. Equivalent IOP lowering found when travoprost is preserved with polyquaternium or benzalkonium chloride. Am J Ophthalmol. 2015;160:266\u201374.","journal-title":"Am J Ophthalmol"},{"key":"65_CR34","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","volume":"135","author":"RK Parrish","year":"2003","unstructured":"Parrish RK, Palmberg P, Sheu W-P, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688\u2013703.","journal-title":"Am J Ophthalmol."},{"key":"65_CR35","first-page":"901","volume":"7","author":"I Lanzl","year":"2013","unstructured":"Lanzl I, Hamacher T, Rosbach K, et al. Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clin Ophthalmol. 2013;7:901\u201310.","journal-title":"Clin Ophthalmol."},{"issue":"6","key":"65_CR36","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jcrs.2015.01.015","volume":"41","author":"RH Brown","year":"2015","unstructured":"Brown RH, Gibson Z, Zhong L, Lynch MG. Intraocular pressure reduction after\u00a0cataract surgery with implantation of a trabecular microbypass device. J Cataract Refract Surg. 2015;41(6):1318\u20139.","journal-title":"J Cataract Refract Surg"}],"updated-by":[{"DOI":"10.1007\/s40123-016-0068-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000}}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-016-0065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-016-0065-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-016-0065-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:11:42Z","timestamp":1628615502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-016-0065-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,12]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["65"],"URL":"https:\/\/doi.org\/10.1007\/s40123-016-0065-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40123-016-0068-0","asserted-by":"object"}]},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,12]]},"assertion":[{"value":"29 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}